We Work For Health Statement on CMS Release of the MFP for IPAY 2027 Selected Drugs

November 26, 2025

(Washington, DC) We Work For Health Executive Director Dan Leonard issued the following statement in response to the administration’s announcement on the Maximum Fair Prices (MFP) for IPAY 2027 selected drugs:

“We Work For Health has been sounding the alarm about the dangers of government price controls since the passage of the Inflation Reduction Act (IRA). This latest announcement from the Administration is yet another troubling consequence of that policy – one that will ripple across the entire innovation ecosystem, affecting everyone from researchers and scientists to the workers who build and maintain R&D facilities.

“Research has shown time and time again that price setting is not the solution for driving down the cost of healthcare in the U.S. Instead, this policy will do irreparable harm to innovation, harming patients and creating uncertainty for new treatments and cures.

“Particularly now, while China is hot on our heels to overtake the U.S. as the global leader in life sciences, we cannot afford to let our medical innovation ecosystem take such a substantial hit.

“We Work For Health remains committed to urging policymakers to reconsider this approach and instead advance solutions, such as insurance company and middlemen reform, that protect innovation, drive economic growth, and ensure patients across America have access to cutting-edge treatments. It is critical to prioritize policies that foster investment in research, uphold high-quality care, deliver real savings for patients and preserve America’s leadership in medical innovation. We look forward to working with our leaders in Washington to put the smart policy solutions into action.”

To learn more, check out We Work For Health’s resources related to the Inflation Reduction Act:

• One-pager: Myths vs. Facts: Inflation Reduction Act

• One-pager: Industry Leaders Discuss Inflation Reduction Act Consequences

• Report: Key Context for CMS Prescription Drug Negotiations 

• Report: The Inflation Reduction Act and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials

• Blog: IRA: Three Letters That Undermine Two Urgent Priorities — Fostering Innovation in Healthcare and Accelerating Economic Growth

• Blog: We Work For Health and Stakeholders Discuss Impact of the IRA